| Autor: |
Flynn NR; Department of Pathology and Immunology, Washington University-St. Louis, St. Louis, MO 63130, USA., Ward MD; Department of Pathology and Immunology, Washington University-St. Louis, St. Louis, MO 63130, USA., Schleiff MA; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Laurin CMC; Department of Chemistry, University of Oxford, Oxford OX1 3TA, UK., Farmer R; Department of Pathology and Immunology, Washington University-St. Louis, St. Louis, MO 63130, USA., Conway SJ; Department of Chemistry, University of Oxford, Oxford OX1 3TA, UK., Boysen G; Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Swamidass SJ; Department of Pathology and Immunology, Washington University-St. Louis, St. Louis, MO 63130, USA., Miller GP; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. |
| Abstrakt: |
The 3,5-dimethylisoxazole motif has become a useful and popular acetyl-lysine mimic employed in isoxazole-containing bromodomain and extra-terminal (BET) inhibitors but may introduce the potential for bioactivations into toxic reactive metabolites. As a test, we coupled deep neural models for quinone formation, metabolite structures, and biomolecule reactivity to predict bioactivation pathways for 32 BET inhibitors and validate the bioactivation of select inhibitors experimentally. Based on model predictions, inhibitors were more likely to undergo bioactivation than reported non-bioactivated molecules containing isoxazoles. The model outputs varied with substituents indicating the ability to scale their impact on bioactivation. We selected OXFBD02, OXFBD04, and I-BET151 for more in-depth analysis. OXFBD's bioactivations were evenly split between traditional quinones and novel extended quinone-methides involving the isoxazole yet strongly favored the latter quinones. Subsequent experimental studies confirmed the formation of both types of quinones for OXFBD molecules, yet traditional quinones were the dominant reactive metabolites. Modeled I-BET151 bioactivations led to extended quinone-methides, which were not verified experimentally. The differences in observed and predicted bioactivations reflected the need to improve overall bioactivation scaling. Nevertheless, our coupled modeling approach predicted BET inhibitor bioactivations including novel extended quinone methides, and we experimentally verified those pathways highlighting potential concerns for toxicity in the development of these new drug leads. |
